New Treatment for Nocturnal Enuresis in Children
Outcome of Treatment of Monosymptomatic Nocturnal Enuresis in Children Using Imipramine Alone Versus Sulbutiamine Alone Versus Imipramine Plus Sulbutiamine : Prospective Comparative Study
Sohag University
450 participants
Mar 1, 2024
INTERVENTIONAL
Summary
The aim of the study is to evaluate the role of sulbutiamine in treatment of monosymptomatic nocturnal enuresis in children by using it alone or as a combination therapy with tricyclic antidepressants (imipramine+sulbutiamine).
Eligibility
Inclusion Criteria2
- Age : 6 - 18 years old.
- All children diagnosed by Primary monosymptomatic nocturnal enuresis in this age group.
Exclusion Criteria6
- Secondary nocturnal enuresis (child who has been continent for at least 6 months before the onset of bedwetting ).
- congenital anomalies (Posterior urethral valve , ectopic ureter , ectopia vesica ,…)
- history of previous lower urinary tract surgery (Multiple hypospadias surgeries ,…, )
- neurogenic bladder (as underactive bladder ).and urge incontinence.
- presence of post-void residual urine greater than 20% of functional bladder capacity.
- history or evidence of disorders in other organs such as (cardiovascular system disease), liver , psychological problems , evident allergic reaction to both medication.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months. it will be used alone in group B and combined with imipramine in group C
imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months. it will be used alone in group A and combined with sulbutiamine in group C
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06497647